A drug safety review of treating eosinophilic asthma with monoclonal antibodies

被引：17

作者：

Mitchell, Patrick ^{[1
]}

Leigh, Richard ^{[1
]}

机构：

[1] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada

来源：

EXPERT OPINION ON DRUG SAFETY | 2019年 / 18卷 / 12期

关键词：

Asthma; biologics; safety; omalizumab; mepolizumab; reslizumab; benralizumab; dupilumab; real world evidence; INADEQUATELY CONTROLLED ASTHMA; ANTIIMMUNOGLOBULIN-E ANTIBODY; SEVERE UNCONTROLLED ASTHMA; SEVERE ATOPIC-DERMATITIS; LONG-TERM EFFICACY; ADD-ON THERAPY; ALLERGIC-ASTHMA; DOUBLE-BLIND; TREATMENT OPTION; POOLED ANALYSIS;

D O I：

10.1080/14740338.2019.1675634

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Introduction: The last two decades have seen significant progress in the treatment of severe asthma especially the severe eosinophilic phenotype. This review article serves to update the reader on the known safety profiles of these medications. It does not serve as a review of their clinical efficacies. Areas covered: All four of the currently approved monoclonal antibodies (biologics) used in the treatment of severe asthma are discussed with reference to the known safety data garnered from clinical trials and real world evidence. A fifth, approved by The European Commission and FDA, but not yet by NICE or Health Canada, is also discussed. Expert opinion: For each of the five biologics the authors shall summarize the known safety profiles and also the potential adverse effects as their usage is extended long term with suggestions for real world studies to help us develop our knowledge base.

引用

页码：1161 / 1170

页数：10

共 87 条

[1] Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan [J].

Adachi, Mitsuru ;

Kozawa, Masanari ;

Yoshisue, Hajime ;

Milligan, Ki Lee ;

Nagasaki, Makoto ;

Sasajima, Takayoshi ;

Miyamoto, Terumasa ;

Ohta, Ken .

RESPIRATORY MEDICINE, 2018, 141 :56-63

[2]

Akinlade B, 2019, BR J DERMATOL

[3] Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting [J].

Ali, Ayad K. ;

Hartzema, Abraham G. .

JOURNAL OF ASTHMA AND ALLERGY, 2012, 5 :1-9

[4]

[Anonymous], 2016, MED LETT DRUGS THER, V58, P81

[5]

Antoniu SA, 2009, EXPERT OPIN INV DRUG, V18, P869, DOI [10.1517/13543780902922678 , 10.1517/13543780902922678]

[6] Represcription of penicillin after allergic-like events [J].

Apter, AJ ;

Kinman, JL ;

Bilker, WB ;

Herlim, M ;

Margolis, DJ ;

Lautenbach, E ;

Hennessy, S ;

Strom, BL .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (04) :764-770

[7] Biological treatments for severe asthma [J].

Assaf, Sara M. ;

Hanania, Nicola A. .

CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 19 (04) :379-386

[8] Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma [J].

Bagnasco, Diego ;

Caminati, Marco ;

Ferrando, Matteo ;

Aloe, Teresita ;

Testino, Elisa ;

Canonica, Giorgio Walter ;

Passalacqua, Giovanni .

BIOMED RESEARCH INTERNATIONAL, 2018, 2018

[9] Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis [J].

Baker, Dana L. ;

Nakamura, Gerald R. ;

Lowman, Henry B. ;

Fischer, Saloumeh Kadkhodayan .

AAPS JOURNAL, 2016, 18 (01) :115-123

[10] Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma [J].

Bel, Elisabeth H. ;

Wenzel, Sally E. ;

Thompson, Philip J. ;

Prazma, Charlene M. ;

Keene, Oliver N. ;

Yancey, Steven W. ;

Ortega, Hector G. ;

Pavord, Ian D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13) :1189-1197

← 1 2 3 4 5 6 7 8 9 →